JAPI REC' DE L'IPTO 03 APR 2006

Substitute fo	U.S. DEPARTMENT OF COMM	ERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER			
TRANSMITTAL LETTER TO THE UNITED STATES			1032013-000119			
	DESIGNATED/ELECTED		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)			
	CONCERNING A FILING U		10/532,114			
INTERN	PCT/FR2003/003124	INTERNATIONAL FILING DATE 21 October 2003	PRIORITY DATE CLAIMED 21 October 2002			
TITLE C	F INVENTION	2 October 2003	Z i October 2002			
PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND A HISTAMINE H2-RECEPTOR ANTAGONIST						
APPLIC	ANT(S) FOR DO/EO/US					
		, Herve FICHEUX, Michel HOMERIN	, Alain TOCCOEN and Yoshio INABA			
		es Designated/Elected Office (DO/EO/US) the f	following items and other information:			
1.		concerning a filing under 35 U.S.C. 371.				
2. 🗙		Submission of items concerning a filing under				
3.	This is an express request to begin n (6), (9) and (22) indicated below.	ational examination procedures (35 U.S.C. 37	1(f)). The submission must include items (5),			
4.	The US has been elected by the exp	ration of 19 months from the priority date (Artic	cle 31).			
5.	A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))				
	a. I is attached hereto (required	only if not communicated by the International B	Bureau).			
	b. as been communicated by	the International Bureau.				
	c. is not required, as the application	ation was filed in the United States Receiving C	Office (RO/US).			
6.	An English language translation of th	e International Application as filed (35 U.S.C. 3	371(c)(2))			
	a. is attached hereto.					
	b. has been previously submitte	ed under 35 U.S.C. 154(d)(4).				
7.	Amendments to the claims of the Inte	ernational Application under PCT Article 19 (35	U.S.C. 371(c)(3))			
	a. are attached hereto (required	d only if not communicated by the International	Bureau).			
	b. have been communicated by	the International Bureau.				
	c. have not been made; however	er, the time limit for making such amendments	has NOT expired.			
	d. have not been made and will	not be made.				
8.	An English language translation of th	e amendments to the claims under PCT Article	e 19 (35 U.S.C. 371(c)(3)).			
9. 🕱	an oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. 🔲	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Itor	ms 11 to 21 below concern documer	at/s) or information included:				
11.						
12.		ng. A separate cover sheet in compliance with	27 CED 2 29 and 2 24 is included			
13.		ig. A separate cover sheet in compliance with	37 GFR 3.20 and 3.31 is included.			
	A FIRST preliminary amendment.	:				
	A SECOND or SUBSEQUENT preliminary amendment.					
15.						
16.	A change of power of attorney and/or					
17.	A computer-readable form of the seq	uence listing in accordance with PCT Rule 13to	er.2 and 37 C.F.R. 1.821 - 1.825.			
18.	A second copy of the published interr	national application under 35 U.S.C. 154(d)(4).				
19.		ge translation of the international application ur	nder 35 U.S.C. 154(d)(4).			
20.	Other items or information: A copy of Missing Requirements under 35 U.	of Notification of Missing Requirements dated S.C. 371 dated 7 February 2006.	7 February 2006; and Response to Notification			

		.10/532,114	n, see 37 CFR 1.5) INTERNATE	PCT/FR2003/003124			1032013-00	
21.			hat the published applicat		assignment		CALCULATIONS	PTO USE ONLY
						<u> </u>		
						_		
22.	×	The following fees are	submitted:					
	Basi	c Filing Fee (1631)						
	Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$ 130.00		
		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		\$	
		l Claims	-20 =		× \$50.00 (161		\$ 0.00	
		pendent Claims		U	* \$200.00 (16		\$ 0.00	
		MULTIPLE DEPENDENT CLAIM(S) (if applicable) * \$360.00 (1616) Examination Fee * \$200.00 (1633)						
		ch Fee			+ \$400.00 (16			
			for each add'i 50 sheets	exceeding 100 sheets)	Ψ-00.00 (10	332)		
	App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets) TOTAL OF ABOVE CALCULATIONS =				\$ 130.00			
	Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					\$ 0.00		
		are reduced by 1/2.			SUBTOT	-,, +	\$ 130.00	
	Processing fee of \$130.00 (1618) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00			
	TOTAL NATIONAL FEE =				EE =	\$ 130.00		
	acco	mpanied by an appropr	ed assignment (37 CFR 1 iate cover sheet (37 CFR			tv +		
-vV	ini.	1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.					\$ 130.00	
. OI	_	_	136.00 UP				Amount to be refunded :	
	a. [A check in the amo	unt of	to cover the above fees	is enclosed.	[charged :	
	b. Please charge my Deposit Account No. <u>02-4800</u> in the amount of duplicate copy of this sheet is enclosed.						to cover the above	e fees. A
	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.						erpayment to	
	d. X Charge \$130.00 to credit card. Form PTO-2038 is attached.							
		NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
	SEN	ID ALL CORRESPOND	ENCE TO:		-n1-	W	11 18	
	Buchanan Ingersoll PC Including attorneys from Burns, Doane, Swecker & Mathis P.O. Box 1404					(' / . ≣	Hazel	
				Мє	lelissa M. Hayworth			
		3) 836-6620			NAME			
					45,7	774	3 A	pril 2006
					DECISTRAT			DATE

Application No.: 10/532,114 Attorney Docket No.: 032013-119

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re F	atent Application of			
Franco	ois SCHUTZE et al.	Group Art Unit:		
Applio	cation No.: 10/532,114	Examiner:		
Intern	ational Filing Date: April 21, 2005	Confirmation No.:		
For:	Pharmaceutical Composition Combining Tenatroprazole and a Histamine H2- Receptor Antagonist			

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371 DATED 7 FEBRUARY 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please note that inventor Alain Taccoen is deceased. Accordingly, pursuant to 37 C.F.R. §1.42l and MPEP § 409.01(a), his heir, Nathalie Taccoen, has signed on his behalf as heir and legal representative to Alain Taccoen.

Accordingly, Applicants submit herewith the attached executed declaration indicating the relationship between the heir and the deceased inventor and the heir's citizenship, residence, and mailing address as required under 37 C.F.R. § 1.497(b)(2).

The heir is as follows:

Nathalie Taccoen
wife of and heir and legal representative to Alain Taccoen
9, avenue de Villiers
F-78150 Le Chesnay
France

As the heir to Alain Taccoen's estate, Nathalie Taccoen has executed the attached oath/declaration in place of Alain Taccoen.

If there are any questions regarding this submission, please contact the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Bv

Melissa M. Hayworth

Registration No. 45,774

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: April 3, 2006